Eur J Pediatr Surg 2012; 22(02): 143-147
DOI: 10.1055/s-0032-1308699
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Benign Bone Defects in Children with Silicate-Substituted Calcium Phosphate (SiCaP)

Hans Joachim Kirschner
1   Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital Tuebingen, Tuebingen, Germany
,
Florian Obermayr
1   Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital Tuebingen, Tuebingen, Germany
,
Juergen Schaefer
2   Department of Diagnostic and Interventional Radiology, University of Tuebingen, Tuebingen, Germany
,
Justus Lieber
1   Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital Tuebingen, Tuebingen, Germany
› Author Affiliations
Further Information

Publication History

07 October 2011

15 October 2011

Publication Date:
19 April 2012 (online)

Preview

Abstract

Background In children with benign bone defects, various treatment options are recommended. Whether these defects should be curetted, osteosynthetically stabilized and/or filled with allogenic or synthetic bone material is still a matter of controversy.

Methods The reported study presents preliminary results of five children with benign bone lesions of the lower extremity. Curettage and filling of the defect with a commercially available silicate-substituted calcium phosphate (SiCaP) (Actifuse® by ApaTech Ltd., Elstree, United Kingdom) was performed. Patients were followed-up in the outpatient clinic. The healing process was assessed according to the clinical and radiological criteria.

Results Clinical and radiological follow-up showed uneventful healing without intraoperative and short-term complications. All patients were capable of full weight bearing after a few weeks and currently did not experience any decreased range of movement among adjacent joints. Growth disturbances did not occur. In all patients increasing cancellous bone reconstruction of the defect, without signs of osteolysis could be shown radiologically.

Conclusion SiCaP represents a good and safe alternative to hitherto existing therapies in the management of defined symptomatic benign bone defects in the pediatric age group.